Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis.
about
TNF-alpha inhibitors for ankylosing spondylitisTNF-alpha inhibitors for ankylosing spondylitisPrevalence, clinical relevance and characterization of circulating cytotoxic CD4+CD28- T cells in ankylosing spondylitisTherapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approachesBiologic agents in juvenile spondyloarthropathiesOld and new treatment targets in axial spondyloarthritisDifferential mechanisms of de-regulated bone formation in rheumatoid arthritis and spondyloarthritisGeneration and differentiation of induced pluripotent stem cells reveal ankylosing spondylitis risk gene expression in bone progenitorsBody mass index is related with the presence of syndesmophyte in axial spondyloarthritis: Data from the Korean College of Rheumatology BIOlogics (KOBIO) registry.Therapeutic advances in ankylosing spondylitis.Anti-TNF-alpha therapy in ankylosing spondylitis.The synovio-entheseal complex in enthesoarthritis.The Nonradiographic Axial Spondyloarthritis, the Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis: The Tangled Skein of Rheumatology.Safety of tumor necrosis factor-alpha inhibitors for treatment of ankylosing spondylitis: A meta-analysis.Osteoblast Role in Rheumatic Diseases.The interleukin 1 gene cluster contains a major susceptibility locus for ankylosing spondylitisGene expression analysis of macrophages derived from ankylosing spondylitis patients reveals interferon-gamma dysregulationTreatment of spondyloarthropathies with antibodies against tumour necrosis factor alpha: first clinical and laboratory experiencesCurrent use of biologicals for the treatment of spondyloarthropathies.Etanercept in the treatment of ankylosing spondylitis: A systematic review and meta-analysis.Spondylarthropathies: options for combination therapy.International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitisTreatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor alpha.New treatment options in ankylosing spondylitis: a role for anti-TNFalpha therapy.Retroperitoneal fibrosis: an extraarticular manifestation of ankylosing spondylitis.Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects.Aberrant expression of shared master-key genes contributes to the immunopathogenesis in patients with juvenile spondyloarthritis.Novel therapies in the treatment of spondyloarthritis.Perspectives for TNF-alpha-targeting therapies.Increased risk of ischemic heart disease in young patients with newly diagnosed ankylosing spondylitis--a population-based longitudinal follow-up study.Emerging role of anti-tumor necrosis factor therapy in rheumatic diseasesTumor necrosis factor-α signaling in macrophages.Th2 mediated regulation in RA and the spondyloarthropathies.Ankylosing spondylitis: introductory comments on its diagnosis and treatment.Juvenile onset spondyloarthropathies: therapeutic aspectsAnti-tumour necrosis factor alpha therapy for ankylosing spondylitis: international experienceRed blood cell distribution width: a potential maker estimating disease activity of ankylosing spondylitis.Recent progress in ankylosing spondylitis treatment.Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases.Association of PTPN22 polymorphsims and ankylosing spondylitis susceptibility.
P2860
Q24186462-75FEE17E-247D-4584-A3F7-B0B877A1E97AQ24246757-6491D35B-C63F-499C-9006-4213974AC863Q24797697-249145F4-1DA7-487D-B63F-6D569F31595BQ24806367-50A13AC9-FA4A-497D-83E0-CF2749A8D496Q26766263-348B7616-6D1F-4ED9-8021-6044D71F06ADQ26777906-9658898E-8F6E-4055-A416-BA6667E86806Q28073386-B12ECFB3-E6CF-4360-BC41-7D11C502A030Q29247925-99A51F3B-E9FF-48CA-811B-24243A214EC1Q31146997-E0FE30FE-62D7-4026-8CE6-779EA54DDB78Q31697579-317BB944-6967-49CE-AC66-36EC5E0DEE85Q33204138-CE6E7E7A-D1D9-4237-AC9D-C6675A95BE7FQ33360030-587F6143-F897-4E25-820B-1F7CF90E1B29Q33710428-2EFA0006-E551-431E-ABEB-80EB0D11D176Q33833623-13EBFF63-1538-4868-8B16-7FBB679B0D91Q33838967-A2139067-9D72-4F54-86AA-397E1C26361BQ33910145-5D997BF3-6E81-491B-AD5E-28F3C28B5244Q33923744-FAEC27A4-8819-4992-90C1-FC3795B8F3D1Q34071316-CE4AB03E-6E45-434B-B8B7-5DEC6D80ABBCQ34240751-D7C1B855-0209-465B-AB8F-7F5F5AD16319Q34292245-5A3BEDA9-DD90-4F01-8959-493096B7872EQ34309710-81C005DA-565A-41AD-B5DF-323B45C29B05Q34536278-C80B625A-0FCA-44C7-BD3E-8679846101C2Q34560557-EDD29C9B-BB8B-4DB8-A0F2-DF1E773AB6A5Q34560574-79A442CD-6263-409C-9443-A83D69B98091Q34601767-57F851CB-D1A8-4E69-875D-15551D303F3CQ34614211-54D2C3DE-7720-4639-A759-F7A5BFF487E0Q34704329-8E269280-59F7-4D08-92E7-DB02AA6A75AEQ34706981-35C69FDC-0AC1-47CC-9DE7-99823E6D90B3Q34731078-63A7964D-8005-458E-A74A-51F502133925Q34731291-BC43D17E-39E8-4DBD-9C72-52661794FB00Q34731307-DA09AB27-2F6D-45A1-8DAF-F55D467DD764Q34734335-272A065E-E972-43B1-A3FF-1A71AFC9664AQ34962858-EFBDA09F-937F-4930-AE58-7ABD4FBB0C67Q34967487-C6D634C0-5CD9-4CDD-8BE7-039F84987DD8Q34967520-1B516D38-2B2B-4FCE-A1D4-C90899168F92Q34967541-DB92A5AB-E2B4-4844-A716-29D255DB52F6Q35017147-EF65AE10-03D4-4C58-AE3D-D7EF44CCB20CQ35040745-57B94E38-D062-4252-B51F-8192892C8F8CQ35116177-3C550C1C-EDFE-4E1C-AA43-6FC379DCB170Q35145104-EAA2F579-F6CA-4B1A-AE83-AA2B663EA7FF
P2860
Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis.
description
1995 nî lūn-bûn
@nan
1995 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Use of immunohistologic and in ...... s with ankylosing spondylitis.
@ast
Use of immunohistologic and in ...... s with ankylosing spondylitis.
@en
Use of immunohistologic and in ...... s with ankylosing spondylitis.
@nl
type
label
Use of immunohistologic and in ...... s with ankylosing spondylitis.
@ast
Use of immunohistologic and in ...... s with ankylosing spondylitis.
@en
Use of immunohistologic and in ...... s with ankylosing spondylitis.
@nl
prefLabel
Use of immunohistologic and in ...... s with ankylosing spondylitis.
@ast
Use of immunohistologic and in ...... s with ankylosing spondylitis.
@en
Use of immunohistologic and in ...... s with ankylosing spondylitis.
@nl
P2093
P356
P1476
Use of immunohistologic and in ...... s with ankylosing spondylitis.
@en
P2093
Seyrekbasan F
P304
P356
10.1002/ART.1780380407
P577
1995-04-01T00:00:00Z